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Abstract
Introduction: Constipation is a common problem in intensive care units. We assessed the efficacy and safety of
laxative therapy aiming to promote daily defecation in reducing organ dysfunction in mechanically ventilated
patients.
Methods: We conducted a prospective, randomized, controlled, nonblinded phase II clinical trial at two general
intensive care units. Patients expected to remain ventilated for over 3 days were randomly assigned to daily
defecation or control groups. The intervention group received lactulose and enemas to produce 1–2 defecations
per day. In the control group, absence of defecation was tolerated up to 5 days. Primary outcome was the change
in Sequential Organ Failure Assessment (SOFA) score between the date of enrollment and intensive care unit
discharge, death or day 14.
Results: We included 88 patients. Patients in the treatment group had a higher number of defecations per
day (1.3 ± 0.42 versus 0.7 ± 0.56, p < 0.0001) and lower percentage of days without defecation (33.1 ± 15.7 % versus
62.3 ±24.5 %, p < 0.0001). Patients in the intervention group had a greater reduction in SOFA score (–4.0 (–6.0 to 0)
versus –1.0 (–4.0 to 1.0), p = 0.036) with no difference in mortality rates or in survival time. Adverse events were more
frequent in the treatment group (4.5 (3.0–8.0) versus 3.0 (1.0–5.7), p = 0.016), including more days with
diarrhea (2.0 (1.0–4.0) versus 1.0 (0–2.0) days, p < 0.0001). Serious adverse events were rare and did not
significantly differ between groups.
Conclusions: Laxative therapy improved daily defecation in ventilated patients and was associated with a
greater reduction in SOFA score.
Trial registration: Clinical Trials.gov NCT01607060, registered 24 May 2012.
Introduction
Constipation is a frequent problem in intensive care
units (ICUs) and has often been overlooked [1]. A number
of factors can contribute to constipation in critically ill
patients, including immobility, dehydration and the use of
sedatives, opioids and vasopressors [1–3]. The reported
incidence of constipation in this population varies from 5
to 84 % [4–9].
Constipation may be part of a broader context of acute
intestinal dysfunction [10]. Recent studies have identified
constipation as an independent prognostic factor in crit-
ically ill patients [1, 2, 9, 11, 12], suggesting that its treat-
ment would improve outcome [13]. Bowel dysfunction
can lead to complications, such as bacterial transloca-
tion, abdominal distension, delayed gastric emptying,
vomiting, intestinal obstruction and perforation [14–17]
and may be associated with worsened prognosis [18].
However, it remains unclear whether constipation is
merely a marker of disease severity or an organ dysfunc-
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Given the absence of relevant studies, we conducted
this phase II study to assess the effects of a laxative ther-
apy protocol aimed at promoting daily defecation on
organ dysfunction in mechanically ventilated patients.
We hypothesized that daily defecation would reduce
bacterial translocation and improve intra-abdominal
pressure by reducing abdominal distention and enhan-
cing gastric emptying, thus contributing to a reduction
in overall organ dysfunction. We also aimed to evaluate
the efficacy of the protocol in promoting daily defecation




The study was an investigator-initiated, prospective, ran-
domized, controlled, nonblinded clinical trial of critically
ill, mechanically ventilated patients admitted to two gen-
eral, mixed ICUs (9 and 17 beds) at a Brazilian university
hospital. We randomly assigned patients in a 1:1 ratio to a
daily defecation group or to a control group in blocks of
10 per unit using sealed opaque envelopes. The study
team was responsible for generating the envelopes, enrol-
ling participants and assigning them to the groups. As the
failure to produce daily defecation in the intervention
group would result in the use of enemas, it was not pos-
sible to blind the intervention. Thus, all members of the
study team and the assistant physicians were aware of
group assignment. The study was registered in Clinical
Trials (NCT01607060). The Ethical Committee of the
Federal University of Sao Paulo approved the study
(number 0844/08), and all patients or their legal represen-
tative gave their written informed consent.
Patients
We enrolled mechanically ventilated patients over 18
years of age during the first 72 hours after ICU admis-
sion who were expected to remain in the ICU and on
mechanical ventilation (MV) for more than 3 days and
who were receiving at least 20 % of their target calories
as enteral nutrition. We excluded those patients with
unstable fractures that may have resulted in limitation of
bed mobility, those who were pregnant, those with
gastrointestinal ostomy (colostomy, ileostomy or jejunost-
omy) or any gastrointestinal disease associated with diar-
rhea, those with chronic liver disease, neuromuscular
diseases, spinal cord injury, severe hemodynamic instability,
survival expectancies of less than 24 hours, those under
palliative care and those previously included in the study.
Study protocol
All patients received treatment until day 28 after inclu-
sion, ICU discharge or death, whichever came first. The
protocol is described in detail in Additional file 1. Briefly,
the intervention group received lactulose (667 mg/ml;
Lactulona®, Daiichi Sankyo, Barueri, SP, Brazil) at an initial
dose of 20 ml every 8 hours. The goal was for the patient
to produce 1–2 defecations per day. Lactulose was discon-
tinued in patients with diarrhea. In the control group, the
absence of defecation was tolerated for up to 5 days, unless
symptoms of obstipation were present. Rectal examination
and enemas were prescribed as needed, and lactulose use
was discouraged. The general treatments and procedures
for weaning from MV for both groups were based on local
protocols. Nutritional support was also based on local
protocols and is briefly described in Additional file 1.
Measurements
Our primary outcome was the change in Sequential
Organ Failure Assessment (SOFA) score between the
date of enrollment (day 0) and the day of ICU discharge,
death or day 15 of the study, whichever came first
(termed ΔSOFA). The secondary outcomes were the
ventilator-free days within 28 days, and the length of
ICU and hospital stays. We determined the 28-day, ICU
and hospital mortality rates. For those patients discharged
from the hospital before day 28, survival status was deter-
mined by consulting with the hospital register for reports
of outpatient clinic visits, hospital readmissions or phone
calls. We used the daily Therapeutic Intervention System
Score (TISS)-28 [19] to assess nurse workload, and the
data were reported as the mean values of the daily TISS-
28 and the total TISS-28 during the study period. We also
recorded the occurrence of new infections, considering
only pneumonia, catheter-related bloodstream infections
and urinary tract infections, the presence of bacteremia,
new episodes of severe sepsis or of septic shock, and the
occurrence of new organ dysfunctions, according to the
definitions available in Additional file 1.
For all patients, we recorded the general descriptive
data as described in Additional file 1. The effectiveness
of the protocol was assessed throughout the treatment
period, primarily by the number of defecations per day,
which was defined as the total number of defecations oc-
curring during the treatment period divided by the total
days of observation. We measured the percentage of
days without evacuation during the observation period
and the time to the first defecation. For patients who did
not defecate during the treatment period, we considered
the number of hours of observation. The percentage of
days in which enemas were used and the mean daily
dose of lactulose were also recorded. We also assessed
the frequency of constipation, defined as the absence of
stools for more than 3 consecutive days without mech-
anical obstruction according to the unit’s protocol for
obstipation management.
We assessed adverse events (AEs) during the entire
study period. We considered only those events with
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higher potential associations with the laxative therapy.
Thus, we focused on the occurrences of diarrhea, vomit-
ing, abdominal distension, dermatitis, pressure ulcers,
electrolyte disturbances (hypernatremia, hypokalemia and
hypomagnesemia), gastric reflux, gastrointestinal bleeding
and Ogilvie's syndrome (see Additional file 1 for details).
We considered diarrhea as the presence of three or more
defecations in a given day as previously defined [20]. Ser-
ious adverse events included Ogilvie's syndrome, any
gastrointestinal bleeding, hypernatremia ≥160 mEq/l,
hypokalemia ≤2.5 mEq/l or hypomagnesemia ≤1.0 mEq/l
and any other serious event that may have been related to
the protocol in the opinion of the attending physician.
Statistical analysis
The sample size calculation was based on a predicted
difference of 2.5 points in the ΔSOFA score considering
a power of 80 % with an error of 0.05. Thirty-six patients
per group would have been necessary. However, we
adjusted the sample by 20 % expecting a non-normal
distribution of this variable. Thus, the final sample size
was 44 patients per group, totaling 88 patients.
All variables were subjected to the Kolmogorov-
Smirnov test to assess their distributions. We described
the categorical variable as number and percentage. The
continuous variables were described as medians and
their respective 25th and 75th percentiles or as the mean
± standard deviation, according to their distributions. To
assess the primary and secondary outcomes we con-
structed a generalized linear model with gaussian family
with identity link, quasipoisson with log link or binomial
with log link as appropriate. All models were controlled
by Acute Physiologic Chronic Health Evaluation (APACHE)
score and SOFA score at baseline. The results were
expressed by relative risk or mean difference between
groups, with their respective 95 % confidence intervals,
estimated with the delta method from a quasipoisson
regression considering median APACHE and SOFA scores
at baseline.
The intention-to-treat analysis included all patients
randomly assigned to the intervention group or to the
control group. The per-protocol analysis included only
those patients who remained under MV for at least 3
days. We used the SPSS 19.0 package for Windows
(IBM, Chicago, Illinois, USA) and R 3.1.1 (R Core Team,
2014). All statistical tests were two-tailed, and the statis-
tical significance was set at 0.05.
Results
From September 2008 to May 2012, 2124 patients were
admitted to the study ICUs. Of these patients, 350 met
the inclusion criteria and 88 patients were randomized.
Figure 1 demonstrates the flowchart of the study. One
patient from the intervention group denied to continue
the participation 20 days after inclusion and at 2 days
before ICU discharge but allowed for the use of the data.
Table 1 shows the baseline data showing no significant
differences between the groups.
The data pertaining to the effectiveness of the protocol
are presented in Table 2. Treatment with lactulose was
Fig. 1 Study flow chart. GI gastrointestinal, ICU intensive care unit
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effective in promoting daily defecation. The patients
included in the treatment group had a higher defecation
rate, a lower time to first defecation, a lower percentage
of days without defecation as well as a lower frequency
of constipation throughout the study. Only four patients
in the intervention group (9.1 %) did not have defecation
for 4 consecutive days and three of them were not concur-
rently receiving enteral nutrition because of surgical inter-
ventions. For the intervention group, the mean duration
of lactulose use was 15.2 ± 7.95 days, and the mean daily
dose of lactulose was 43.5 ± 20.55 ml. Only one patient in
the control group used a single dose of lactulose during
the entire treatment period.
There were no differences between the groups with re-
gard to the percent target caloric intake, gastric residue
volume or prokinetic use (Additional file 1: Table S1).
Additionally, there were no differences between the
groups in the use of sedatives, opioids, neuromuscular
blocking agents, vasoactive drugs or insulin (Additional
file 1: Table S2). The nurse workload, assessed by the
TISS-28 score, was not different between the groups
(Table 3).
The data pertaining to the primary and secondary
outcomes are presented in Table 3. The median days
for outcome assessment were 13.5 (7.2–19.7) days in
the control group and 14.0 (8.0–20.7) days in the
Table 1 Baseline characteristics of the patients in both study groups
Variable All patients Intervention Control p value
(n = 88) (n = 44) (n = 44)
Male gender 54 (61.4) 29 (65.9) 25 (56.8) 0.381
Age, years 51.2 ± 19.6 50.4 ± 18.5 52.0 ± 20.8 0.697
Admission category 0.373
Medical 30 (34.1) 13 (29.5) 17 (38.6)
Elective surgery 1 (1.1) 0 1 (2.3)
Emergency surgery 57 (64.8) 31 (70.5) 26 (59.1)
ICU cause of admission 0.822
Polytrauma 21 (23.9) 12 (27.3) 9 (20.5)
Sepsis 20 (22.7) 10 (22.7) 10 (22.7)
Intracranial hemorrhage 14 (15.9) 7 (15.9) 7 (15.9)
TBI 11 (12.5) 6 (13.6) 5 (11.4)
Respiratory failure 5 (5.7) 3 (6.8) 2 (4.5)
Other 17 (19.3) 6 (13.6) 11 (25.0)
Sepsis at enrollment 47 (53.4) 22 (50.0) 25 (56.7)
Severe sepsis 14 (15.9) 4 (9.1) 10 (22.7) 0.103
Septic shock 33 (37.5) 18 (40.9) 15 (34.0)
Comorbidities
Hypertension 32 (36.4) 16 (36.4) 16 (36.4) 1.000
Diabetes mellitus 16 (18.2) 7 (15.9) 9 (20.5) 0.580
Stroke 8 (9.1) 4 (9.1) 4 (9.1) 1.000
Cancer 7 (8.0) 4 (9.1) 3 (6.8) 0.694
COPD 4 (4.5) 1 (2.3) 3 (6.8) 0.306
APACHE II, points 19.5 (15.0–22.0) 20.0 (16.0–24.0) 17.5 (14.0–22.0) 0.075
SOFA at enrollment, points 7.5 (6; 10) 9 (6–11) 7 (6–9) 0.294
TISS-28 at enrollment 37.5 (32.2–41.7) 36.0 (33.0–40.5) 38.0 (31.0–42.0) 0.738
Lactate at enrollment, mmol/l 1.7 (1.3–2.1) 1.6 (1.2–2.1) 1.7 (1.3–2.1) 0.512
Time to ICU admission, days 1.0 (0.7–3.0) 1.0 (0–3.0) 2.0 (1.0–4.0) 0.388
Time to enrollment, hours 50.5 (32.0–66.0) 46.0 (33.0–66.0) 51.0 (30.0–67.0) 0.897
p values determined by Chi-square test, Student’s t-test and Mann-Whitney test as appropriate
Time to ICU admission = time between hospital admission and ICU admission
Time to enrollment = time between ICU admission and study enrollment
Results are expressed as number (%), mean ± standard deviation, or median (25th–75th percentile)
APACHE II Acute Physiology and Chronic Health Evaluation II, COPD chronic obstructive pulmonary disease, ICU intensive care unit, SOFA Sequential Organ Failure
Assessment, TBI traumatic brain injury, TISS-28 Therapeutic Intervention Scoring System-28
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Table 2 Effectiveness of the protocol
Variable Intervention Control p value
(n = 44) (n = 44)
Number of defecation per daya 1.3 ± 0.42 0.7 ± 0.56 <0.001
Time to the first defecation, hoursb 14.5 (4.5–24.0) 96.0 (50.5–127.5) <0.001
Days without defecation, % days 33.1 ± 15.7 62.3 ± 24.5 <0.001
Constipation, number of patientsc 4 (9.1 %) 32 (72.7 %) <0.001
Enema administration, % days 21.1 (10.8–28.4) 4.5 (0–11.6) <0.001
p values determined by Student's t-test and Mann-Whitney test as appropriate
Results are expressed as number of patients (%), mean ± standard deviation or median (25th–75th percentile)
aDefined as the total number of defecations occurring during the treatment period divided by the total days of observation
bFor patients who did not defecate during the treatment period, the number of hours of observation was considered
cDefined as the absence of defecation for at least 4 consecutive days
Table 3 Clinical outcomes of patients in both study groups
Variables Intervention Control Mean difference p valuea
(n = 44) (n = 44) (control – intervention) or relative risk (95 % CI)a
Primary outcome
ΔSOFAb –4.0 (–6.0 to 0) –1.0 (–4.0 to 1.0) –1.907 (–3.683 to 0.13)c 0.036
SOFA at outcome assessment 4.0 (3.0 to 7.0) 5.5 (3.0 to8.7) - -
Secondary outcomes
TISS-28 score
Daily average 31.2 ± 6.41 30.7 ± 5.28 0.077 (–2.335 to 2.49)c 0.949
Total sum 419.0 (252.5 to 640.5) 433.0 (224.5 to 610.0) 24.4 (–73.8 to 122.7)c 0.622
Length of ICU stay (days) 16.0 (10.0 to 23.0) 16.0 (10.0 to 21.0) –1.843 (–5.119 to 1.433)c 0.277
Length of hospital stay (days) 32.5 (18.2 to 49.5) 27.0 (17.0 to 56.7) –3.19 (–28.275 to 21.894)c 0.804
New infection 19 (43.2) 12 (27.3) 1.673 (0.936 to 3.149)d 0.087
Number of new infections 0 (0 to 1.0) 0 (0 to 1.0) 1.627 (0.821 to 3.325)d 0.172
Pneumonia 17 (38.6) 10 (22.7) 1.79 (0.936 to 3.655)d 0.085
UTI 4 (9.1) 2 (4.5) 2.531 (0.508 to 17.677)d 0.264
CRBSI 2 (4.5) 2 (4.5) 0.815 (0.094 to 6.994)d 0.836
Bacteremia 5 (11.6) 9 (20.9) 0.397 (0.128 to 1.124)d 0.067
Severe sepsis/septic shock 12 (27.6) 14 (31.8) 0.842 (0.428 to 1.625)d 0.607
New organ dysfunction 23 (52.3) 24 (54.5) 0.932 (0.621 to 1.396)d 0.726
Ventilator-free days in 28 days 16.5 (11.0 to 21.7) 20.0 (13.2 to 24.0) –1.371 (–4.569 to 1.826)c 0.396
Mortality
Day 28 10 (22.7) 16 (36.4) 1.29 (0.973; 1.715)d 0.081
ICU 11 (25.0) 17 (38.6) 1.311 (0.975; 1.767)d 0.077
Hospital 13 (29.5) 19 (43.2) 1.294 (0.932; 1.803)d 0.129
Results are expressed as number (%), mean ± standard deviation or median (25th to 75th percentile)
aGeneralized linear model with gaussian family with identity link or quasipoisson with log link, or binomial with log link as appropriate; models were controlled by
APACHE score and SOFA at baseline
bΔSOFA is the change in SOFA score between the date of enrollment (day 0) and the day of outcome assessment. Outcome was assessed at ICU discharge, death
or day 15 after enrollment, whichever came first
cmean difference between groups estimated with delta method from a quasipoisson regression considering median APACHE and SOFA scores at baseline
dRelative risk
APACHE Acute Physiologic Chronic Health Evaluation, CI confidence interval, CRBSI catheter-related bloodstream infection, ICU intensive care unit, SOFA Sequential
Organ Failure Assessment score, TISS-28 Therapeutic Intervention Scoring System-28, UTI urinary tract infection
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intervention group (p = 0.567). In the control group,
24 patients were assessed before day 14; 10 of them
died during ICU stay. In the intervention group, 23
patients were assessed before day 14 and six of them
died in the ICU, with no differences between the
groups (p = 0.260). For the intention-to-treat analysis,
the reduction in SOFA scores was greater in the
intervention group (–4.0 (–6.0 to 0) versus –1.0 (–4.0
to 1.0), p = 0.036). The differences between the indi-
vidual components of SOFA scores are presented in
Additional file 1: Table S3. There were no differences
in any of the secondary outcomes. There was no sig-
nificant improve in survival in the intervention group
(p = 0.166; Fig. 2). Five patients remained on MV for
less than 3 days, including three in the intervention
group and two in the control group. The per-protocol
analysis confirmed that the difference in ΔSOFA was
significant (Additional file 1: Tables S4 and S5).
AEs were more frequent among the patients in the
study group, with higher incidences of diarrhea, abdom-
inal distension and vomiting. There were few serious
adverse events reported in either group, and their inci-
dences did not significantly differ between the groups
(Table 4).
Discussion
In this phase II study, we demonstrated that the use of
laxative therapy with lactulose was effective in inducing
defecation in critically ill, mechanically ventilated pa-
tients. Our results suggest that laxative therapy is a safe
Fig. 2 Kaplan-Meier curve demonstrating the 28-day survival of the ICU patients according to their group allocation. Cox proportional hazards
analysis results following adjustment for the category of admission, APACHE score, age and SOFA score (hazard ratio 1.772, 95 % confidence interval
0.789 to 3.978.51; p = 0.166) are shown. Dotted line intervention group; filled line control group
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procedure. The protocol was not accompanied by an in-
crease in the incidence of serious AEs, although a slight
increase in minor AEs, such as diarrhea, abdominal dis-
tension and vomiting, occurred in the intervention
group. In addition, the nursing staff workload was not
affected by the treatment. Laxative therapy aimed at
daily defecation was associated with a greater reduction
in the SOFA score at discharge, death or after 14 days of
treatment.
Some studies have related constipation to the failure to
wean from MV, to an increased length of hospitalization,
and even to the degree of organ dysfunction and
death [1, 9, 11, 13]. van der Spoel et al. published a ran-
domized clinical trial assessing the impacts of laxatives,
lactulose and polyethyleneglycol on early defecation [13].
These authors demonstrated a shorter ICU stay for the
group receiving lactulose, and a multivariate analysis iden-
tified APACHE II and the number of defecations as inde-
pendent predictors of mortality. This study, however, did
not evaluate the impacts of laxative use on organ dysfunc-
tion or on the development of new infections. Masri et al.
randomized 100 patients to receive or to not receive lactu-
lose only during the first 3 days of ICU admission as a
prophylaxis for constipation [21]. The times of the first
bowel movements differed between the groups. They were
not able to show any significant differences in the other
outcomes except for the shorter duration of MV observed
in those patients who defecated after the fifth day. How-
ever, they did not report the MV results on the ventilator-
free days. Neither study was designed to assess the
impacts of daily laxation treatment. Our study focused on
daily laxation, and our results suggest that the interven-
tion might be associated with a greater reduction in organ
dysfunction.
The association of obstipation with poor prognosis has
been suggested previously [1, 2, 9, 11, 12]; however, a
causality effect has never been demonstrated. Our study
aimed to assess the efficacy of our protocol and its im-
pact on the degree of organ dysfunction and not the
underlying physiological mechanisms. Thus, we cannot
explain our findings but rather generate hypotheses.
First, the use of laxation may have reduced intestinal
Table 4 Adverse events of the patients in both study groups
Variable Intervention Control p valuea
(n = 44) (n = 44)
Adverse events
Patients with AE 43 (97.7) 41 (93.2) 0.306
AE per patient 4.5 (3.0–8.0) 3.0 (1.0–5.7) 0.016
AE per patient/day 0.35 (0.2–0.5) 0.2 (0.1–0.3) 0.002
Diarrheab 41 (93.2) 26 (59.1) <0.001
Diarrhea, % days 17.0 (9.3–25.0) 6.3 (0–14.7) <0.001
Diarrhea, days with 2.0 (1.0–4.0) 1.0 (0–2.0) <0.001
Gastric reflux ≥500 ml/dayb 18 (40.9) 19 (43.2) 0.829
Gastric reflux, ml/day 76.5 (29.0–117.7) 61.5 (22.2–112.2) 0.350
Abdominal distensionb 8 (18.2) 2 (4.5) 0.044
Vomitingb 11 (25.0) 4 (9.1) 0.047
Hypernatremiab 4 (9.1) 7 (15.9) 0.334
Hypokalemiab 24 (54.5) 18 (40.9) 0.200
Hypomagnesemiab 13 (29.5) 18 (40.9) 0.265
Decubitus ulcerb 4 (9.1) 5 (11.4) 0.725
Dermatitisb 2 (4.5) 1 (2.3) 0.557
Serious adverse event 5 (11.4) 3 (6.8) 0.461
Ogilvie syndrome, number of patients 2 (4.5) 0 (0) 0.153
Gastrointestinal bleeding, number of patients 1 (2.3) 1 (2.3) ~1.00
Severe hypomagnesemia 1 (2.3) 0 (0) >0.99
Severe hypokalemia 1 (2.3) 1 (2.3) ~1.00
Severe hyponatremia 0 (0) 1 (2.3) >0.99
Results are expressed as number (%) or median (25th–75th percentile)
aChi-square and Mann-Whitney test as appropriate
bResults reported as number of patients with event
AE adverse event
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flora overgrowth, which may have contributed to re-
duced bacterial translocation and expression of bacterial
products in the mucosal epithelium, decreasing the pro-
duction of proinflammatory mediators as previously sug-
gested [22–24]. Obstipation may also have contributed
to abdominal hypertension. Abdominal compartment
syndrome has been associated with worse prognosis in
critically ill patients [25–27]. Possible mechanisms are a
worsening in respiratory function [28] and the interference
with the intra-abdominal or the diaphragmatic work of
breathing [29] as well as reduced splacnic perfusion [30].
As expected, there was an increased incidence of diar-
rhea in the laxative therapy group as well as a slightly
higher incidence of abdominal distention and vomiting.
There was no increase in the objective measurement of
gastric reflux. Two of the patients in the intervention
group had Ogilvie’s syndrome. Although lactulose is as-
sociated with abdominal distention, its use has not been
associated with a higher incidence of Ogilvie’s syndrome
in a previous study [13]. This syndrome has been associ-
ated with many conditions that are prevalent in critically
ill patients [31]. Moreover, lactulose has been widely
used in ICUs as part of the treatment of hepatic enceph-
alopathy with similar doses and Ogilvie’s syndrome is
not reported as a complication of this treatment.
Our study has some strengths. This was a prospective,
randomized study including consecutive patients. Our
protocol was carefully designed to produce daily evacu-
ation, and the ICU team was informed of the protocol
steps, resulting in well-separated study groups. We con-
ducted a comprehensive evaluation of the concomitant
medications to assure that the randomized groups were
balanced. We also assessed the safety of the intervention,
including the occurrence of AEs and the impact of this
strategy on the nurse workload in the ICU.
This study also has some limitations. It is a single-
center, phase II trial with a small sample size, including
only mechanically ventilated patients receiving enteral
nutrition, which limits the external validation of the re-
sults and the evaluation of mortality or of other long-term
outcomes. The nonblinded design also may have caused
bias. A blinded study, using placebo, would not be feasible.
Lactulose is difficult to blind due to its natural effects.
Moreover, the intervention was daily defecation rather
than to test the effects of lactulose. Thus, the use of
enemas in the absence of bowel movement only in the
intervention group would have been impossible if the
study was nonblinded. The use of a placebo enema in the
control group could have generated bowel stimulus and
consequent evacuation. However, this bias was minimized
because the study staff were not directly responsible for
the clinical management of the patients. We also did not
evaluate the presence of intra-abdominal hypertension.
Possible differences between the groups in this parameter
would have helped to better understand one of the pos-
sible physiological mechanisms by which treating obstipa-
tion would reduce organ dysfunction. We could also have
used ultrasonography to evaluate the degree of fecal im-
paction and to assess bowel movements, as well as to ob-
jectively evaluate abdominal distension, one of our major
potential AEs associated with lactulose use. We recognize
that abdominal distension was only subjectively assessed
and this might be biased because of the nonblinded nature
of our study. However, abdominal distension was more
commonly described in the intervention group, which is
an indirect indicator of reduced risk of bias. Another limi-
tation is the absence of data on cumulative fluid balance.
Capillary leak and excessive resuscitation with crystalloids
are associated with increased gut wet-to-dry ratio and
bowel edema resulting in decreased bowel contractility
and abdominal hypertension [32]. If fluid balance was dif-
ferent between the groups we could hypothesize that there
was a higher chance of constipation as well as abdominal
compartment syndrome and this would impact in the
effectiveness of our protocol. However, fluid balance is
highly related to severity of illness and the severity of
illness, even if not significant, seems to be greater in the
intervention group.
Thus, our results should be interpreted with caution.
Future studies with adequate sample sizes are needed to
further understand the effects of this therapy on mortal-
ity in critically ill patients.
Conclusion
Our laxative therapy protocol was able to improve daily
defecation in mechanically ventilated patients and was
associated with a greater reduction in the SOFA score at
discharge, death or after 14 days despite a small increase
in nonserious AEs.
Key messages
 Obstipation is a common problem in critically ill
patients as demonstrated by the time for first
defecation and number of defecations per day in our
control group.
 Treatment with lactulose was effective in promoting
daily defecation. Patients in the treatment arm had a
higher number of defecations per day, a shorter
period for the first defecation and a lower percentage
of days without defecation throughout the study.
 Although there was no difference in the survival
time or in mortality, the daily defecation protocol
was associated with a greater reduction in SOFA
scores as compared with the control arm.
 The intervention was also associated with an
increase in nonserious AEs, such as diarrhea,
abdominal distension and vomiting.
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